As an aside, p53 inactivation by NS2A has implications for studies that propose to use ZIKV as an oncolytic agent for glioblastoma [64–67], since 68% of glioblastoma tumors harbor wild-type p53 [68]. The gene discussed is TP53; the disease is glioblastoma.